GHK-Cu topical vs injection: what the studies show

Answer first

On the skin, GHK-Cu is a listed cosmetic ingredient; injected, it is an unapproved medicine on an FDA risk list. Almost nothing crossed intact human skin in the laboratory. Both controlled human trials used creams and missed their objective targets. For injection, animal studies and one uncontrolled mixture study could be found. No direct comparison could be found.

At a glance

How each form reaches the body

GHK is a three-part peptide made of glycine, histidine and lysine, found in human blood serum ^[1]. In GHK-Cu it is bound to one copper ion ^[2]. No measurement of how the complex travels through a human body could be found for either form. What follows comes from donated skin, from rats and from the test tube.

On the skin. The outer layer of skin is a barrier built to keep molecules out. Two laboratory studies measured how much GHK-Cu gets past it.

• Intact skin. In donated human skin, "almost no peptide or copper permeated through intact human skin" ^[3].
• Skin pierced with tiny needles. Through skin pre-treated with microneedles, 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper crossed in nine hours ^[3].
• Thinned skin, flooded with solution. In skin cut down to thin layers, 136.2 ± 17.5 µg of copper per square centimetre crossed in 48 hours. Between 82 and 97 µg per square centimetre stayed in the tissue ^[4]. That set-up used saturating conditions, which is not how a cream is used.

A 2025 formulation review finds published information on skin permeability "insufficient" ^[5]. One registry entry plans to measure blood levels of the peptide under a patch in 100 people; it has not yet started recruiting ^[6].

By injection. An injection places the substance under the skin barrier altogether. The only measurement of how long GHK lasts after injection comes from rats, where it broke down fast ^[7]. No half-life, spread or availability in people could be found for any route ^[7].

• Copper in the blood. In the test tube GHK competes with albumin, the main blood protein, for copper. At concentrations found in blood, only about 6 per cent of the copper sat on small molecules ^[8].
• The body's own GHK. One study measured natural GHK in blood at 133.0 ± 54.54 ng/ml in 11 healthy adults ^[9]. That is a snapshot of a natural molecule, not a test of a treatment.
• The gut is skipped as well. The gut regulates how much copper is taken up from food. Injection removes that control entirely ^[10].

What the forms share. The cell findings behind both uses come from dishes. In cultured human skin cells, collagen production peaked at 10⁻⁹ mol/l ^[11]. Such concentrations describe the liquid around cells and say nothing about what reaches a cell through skin or from a syringe.

What the studies show

No study comparing the two forms directly could be found in the sources reviewed for this page. The studies below each used one form, in different species, with different endpoints. Their results cannot be set against each other.

How much evidence there is overall

Systematic review A 2026 review included 20 studies of GHK-Cu: 18 preclinical and 2 randomised controlled trials ^[12]. The two controlled trials in people described below both applied the substance to the skin. The authors call the findings "constrained by methodological variability and a limited number of well-designed clinical studies" ^[12].

Registered trials No verified trial of GHK-Cu on its own is registered ^[6]. One completed entry tests a device with a booster serum in 27 people, and the patch entry measures blood levels. Neither gives GHK-Cu as the treatment under test.

Applied to the skin: studies in people

Human RCT The largest controlled trial compared three creams in 86 patients with venous leg ulcers. Silver sulfadiazine at 1 per cent shrank the ulcers more than the other two. Between a copper tripeptide cream at 0.4 per cent and an inert dummy cream, "There was no difference between the latter two treatments." ^[13]

Human RCT Thirteen patients completed a trial of a GHK-Cu skin care regime after laser resurfacing, followed for 12 weeks. The authors report that "objective evaluation found no significant improvement in wrinkles or overall skin quality" ^[14]. Only self-reported satisfaction was higher (p = 0.04).

Human RCT, combination product In 45 men with pattern hair loss, six months of a daily solution raised the hair count by 52.6 and 71.5 in two groups, against 9.6 on placebo ^[15]. The product was a complex of 5-aminolaevulinic acid and copper-free GHK. No share of the result can be pinned on GHK-Cu.

Case reports Four case reports applied a copper peptide with laser-assisted delivery, alongside topical finasteride ^[16]. That design cannot isolate a single ingredient.

Applied to the skin: animal data

Animal data In rats with poorly supplied open wounds, the wound area shrank by 64.5 per cent under a copper tripeptide gel by day 13. Under the gel without the peptide it shrank by 45.6 per cent, and without treatment by 28.2 per cent ^[17]. An animal result does not carry over to people.

Injected: studies in people

Observational, mixture The only injected use in people that could be found is an open study in 1000 patients. They received injections into the skin of a formulation holding five growth factors, thymosin beta-4 and Copper Tripeptide-1 ^[18]. Less shedding was reported in 83 per cent. There was no control group, and no single ingredient can be credited.

No data No study of injected GHK-Cu on its own in people could be found in the sources reviewed for this page. No dose-finding study of injected GHK-Cu in people could be found either.

Injected or placed inside the body: animal data

Animal data In rat wound chambers, repeated doses raised dry weight, DNA, protein, collagen and glycosaminoglycans in a concentration-dependent way. An inactive control tripeptide did nothing ^[19]. A later study in the same model found that the peptide stretched out the expression of the tissue-remodelling enzyme MMP-9 ^[20].

Animal data In 72 rats after cruciate ligament reconstruction, the peptide went straight into the knee joint. The joint was less lax at six weeks in the lower-concentration group. By twelve weeks that difference had gone, and the authors call the effect transient ^[21].

Further mouse studies on lung and gut inflammation are summarised on the GHK-Cu monograph. The sources reviewed here do not record which route they used, so they are left out of this comparison.

Why the two columns cannot be merged

The skin studies measured ulcers, wrinkles, hair counts and wounds on the surface. The injected studies measured tissue inside chambers and joints in rats. No endpoint, species and dose were shared, so no figure on this page shows that one form reaches more, lasts longer or does more.

Doses used in the studies

The doses below are simply what the cited studies gave, listed so that the results can be understood. They are not advice on how to use anything.

The route column is the point of this table. Every human row is topical, and every row placed inside the body is a rat. Nothing here transfers between routes, and a concentration in a cream cannot be converted into an amount in a syringe.

Safety and side effects

The two forms are covered very unevenly. There is one formal safety assessment, and it covers creams at low concentrations. For injection, no controlled safety data could be found.

On the skin

• One cosmetic assessment. An expert panel concluded in 2014 that the ingredients reviewed "are safe in the present practices of use and concentration in cosmetics" ^[22]. The verdict is bound to concentrations of 1 to 30 ppm, with under 10 ppm usual.
• Higher strengths are unassessed. Products sold today often sit well above those levels, and for them no independent safety assessment could be found ^[22].
• Partly borrowed data. The panel leaned on "negative repeated dose toxicity, skin irritation and sensitization, and genotoxicity data". A good share came from trade materials containing palmitoyl tripeptide-1 rather than GHK-Cu itself ^[22].
• Copper on skin is not inert. A study of several copper compounds in skin cells found that their potential to irritate skin "is often overlooked" ^[23].
• An open warning. In 2013 the panel minuted that "some small peptides are potent stimulators of angiogenesis", the growth of new blood vessels. This "might then be an issue" in people with undiagnosed skin cancer. The final report dropped the point, and no experiment addressing it could be found ^[24].

By injection

• A named immune risk. The FDA states that injectable GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." ^[25] Immunogenicity means the chance of an immune reaction.
• No toxicology for the route. The FDA itself notes limited data in humans ^[25]. No toxicology study of the injected route could be found in any species in the sources reviewed for this page. No study confirming or ruling out the immune concern could be found either.
• Purity has no test standard. Commercial material is "approximately 95% pure, but often includes small amounts of mildly neurotoxic materials" ^[22]. No pharmacopoeia monograph could be found, so injectable material has no recognised test standard ^[26].
• Copper load. GHK-Cu is roughly 15.8 per cent copper by mass, calculated from the formula ^[2]. Europe's food safety authority set 5 mg a day as the adult limit, a figure that describes swallowing ^[10]. No measurement of copper balance under repeated injection could be found.

Reports without a clear route. A query of the FDA adverse event database on 7 September 2026 returned two serious reports for GHK-Cu. One describes anaphylactic shock, the other an adverse reaction and a lymphatic malignancy ^[27]. Several peptides had been taken together, and spontaneous reports cannot establish cause. The query summary used here does not record the route.

Chemistry that applies to both. With vitamin C present, a copper peptide complex was shown to cut DNA and protein as early as 1983 ^[28]. This page does not rank the two forms.

Legal status

GHK-Cu is not approved as a medicine in any of the seven markets checked on 7 September 2026, in any form ^[26]. As a cosmetic ingredient it is listed as Copper Tripeptide-1, with the function skin conditioning ^[29]. The FDA names injectable GHK-Cu among substances that may present significant safety risks ^[25]. It is not on the American list of substances pharmacies may compound with ^[30]. The 2026 Prohibited List does not name it. Injected forms fit class S0; no official clarification for topical cosmetics could be found ^[31]. More detail is at peptides banned in sport.

Switching between forms

No study that switched people or animals from one form to the other could be found in the sources reviewed for this page. The same holds for using both forms together. Hybrid methods such as tiny needles ^[3] or laser-assisted delivery ^[16] were used only to help a topical product past the skin.

The blend directory on this site lists four products that contain GHK-Cu: GHK-Cu + BPC-157, GHK-Cu + KPV, the GLOW Peptide Blend and KLOW. Each mixes GHK-Cu with other peptides, and the directory describes none of them as an approved medicine. No study of these mixtures could be found.

This page gives no conversion between a cream and an injection, and no amounts or schedule for either. The full record is on the GHK-Cu monograph.

Frequently asked questions

Which is better, topical or injected GHK-Cu?

Neither form can be called better on the evidence, because no study comparing them directly could be found. Both controlled human trials used creams, in leg ulcers and after laser treatment, and both missed their objective targets. The injected data come from rats and from one uncontrolled mixture study in people.

Is topical or injected GHK-Cu safer?

That cannot be answered from the sources. Creams have one expert safety assessment, from 2014, covering the low concentrations then in use. For injection no controlled safety data could be found, and the FDA names a possible immune risk. Missing data are not evidence of safety.

What is the difference between topical and injectable GHK-Cu?

It is the same molecule on two legal tracks. On the skin it is the listed cosmetic ingredient Copper Tripeptide-1, and almost none of it crossed intact human skin in the laboratory. Injected, it bypasses the skin barrier and is an unapproved medicine that the FDA names among substances that may present significant safety risks.

Can topical and injected GHK-Cu be used together?

This page answers only what the research shows, not how to use anything. No study that combined the two forms, or switched from one to the other, could be found. The blend directory lists four GHK-Cu mixtures with other peptides, and no study of those mixtures could be found either.

Does topical GHK-Cu get through the skin?

In donated human skin, almost no peptide and almost no copper crossed skin that was left intact. Measurable amounts appeared after the skin had been pre-treated with tiny needles, or cut into thin layers and flooded with solution. Neither set-up matches spreading a cream.

Has injected GHK-Cu been tested in people?

No study of injected GHK-Cu on its own in people could be found. The one injected use found is an open study in 1000 patients without a control group. Its formulation also held five growth factors and thymosin beta-4. No dose-finding study in people could be found.

Is injectable GHK-Cu approved?

No. GHK-Cu is not approved as a medicine in any of the seven markets checked on 7 September 2026. The FDA names injectable GHK-Cu among bulk substances that may present significant safety risks. A cosmetic listing covers creams and does not extend to a syringe.

Is GHK-Cu banned in sport?

It is not named on the 2026 Prohibited List. Injected GHK-Cu fits the wording of class S0, which covers drug-like substances no health authority has approved. A cosmetic applied to the skin is a different case, and no official clarification could be found.